MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xkme.2024.100879

Медицинская библиотека · Kidney medicine · 2024

Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A Large Retrospective Cohort Study From United States Clinical Care.

van Boemmel-Wegmann Sascha, Bauer Chris, Schuchhardt Johannes, Hartenstein Alexander, James Glen, Pessina Elena, Beeman Scott, Edfors Robert, Pecoits-Filho Roberto

СтатьяПеревод в очереди

Аннотация

RATIONALE &

OBJECTIVE

Estimates of the incidence of hyperkalemia in patients with chronic kidney disease (CKD) vary widely. Our objective was to estimate hyperkalemia incidence in patients with CKD from routine clinical care, including by level of kidney damage or function and among important patient subgroups.

STUDY

DESIGN

Retrospective cohort study.

SETTING &

PARTICIPANTS

1,771,900 patients with stage 1-4 CKD identified from the US Optum De-Identified electronic health records database.

EXPOSURES OR PREDICTORS: Impaired kidney damage or function level at baseline based on urinary albumin-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR), respectively, and selected patient subgroups.

OUTCOMES: Hyperkalemia: 2 elevated serum potassium values (≥5.5 mmol/L) from the inpatient setting (2-24 hours apart) or outpatient setting (maximum 7 days apart), or 1 elevated serum potassium value plus pharmacotherapy initiation or hyperkalemia diagnosis (maximum 3 days apart).

ANALYTICAL APPROACH: Incidence rates of hyperkalemia were calculated. Estimates were stratified by UACR and eGFR level at baseline and patient subgroups.

RESULTS

Over a mean follow-up of 3.9 years, the incidence of hyperkalemia was 3.37 events/100 person-years (95% confidence intervals, 3.36-3.38). Higher incidence rates were observed with increased UACR and lower eGFR. Highest rates were observed with UACR ≥3,500 (up to 19.1/100 person-years) irrespective of decreased eGFR level. High rates also occurred in patients with type 2 diabetes mellitus (T2DM, 5.43/100 person-years), heart failure (8.7/100 person-years), and those prescribed steroidal mineralocorticoid receptor antagonists (sMRAs, 7.7/100 person-years).

LIMITATIONS: Potential misclassification of variables from possible medical coding errors; potential data incompleteness issues if patients received care at institutions not included in Optum.

CONCLUSIONS

Hyperkalemia is a frequent occurrence in CKD, particularly in patients with T2DM, heart failure, or prescribed sMRAs, indicating the need for regular serum potassium and UACR monitoring in this patient population to help mitigate risk.

Для цитирования: van Boemmel-Wegmann Sascha, Bauer Chris, Schuchhardt Johannes, Hartenstein Alexander, James Glen, Pessina Elena, Beeman Scott, Edfors Robert, Pecoits-Filho Roberto. Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A Large Retrospective Cohort Study From United States Clinical Care.. Kidney medicine. 2024. DOI: 10.1016/j.xkme.2024.100879.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.